Last reviewed · How we verify
NCT05923502
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
trial testing Duvelisib in Follicular Lymphoma in 200 participants. Not yet recruiting.
30 November 2027
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 20 October 2023 |
| Primary completion | 30 November 2027 |
| Estimated completion | 30 November 2027 |
Drugs / interventions tested
- Duvelisib (DUVELISIB) — full drug profile →
Conditions studied
- Follicular Lymphoma — all drugs for Follicular Lymphoma →
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — all drugs for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma →
- Richter Syndrome — all drugs for Richter Syndrome →
- Marginal Zone Lymphoma — all drugs for Marginal Zone Lymphoma →
Sponsor
Ruijin Hospital
Who can join
18 and older, any sex, with Follicular Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05923502
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Duvelisib
Trials testing the same drug.
- NCT07293403 — Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas · Phase 2 · not yet recruiting
- NCT07001384 — A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (AL · Phase 1 · recruiting
- NCT06810778 — Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · Phase 1, PHASE2 · recruiting
- NCT04639843 — Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma · Phase 1 · withdrawn
- NCT05508659 — A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors · Phase 1, PHASE2 · unknown
Other recruiting trials for Follicular Lymphoma
Currently open trials in the same condition.
- NCT07128641 — Odronextamab in Low Tumor Volume Advanced FL · Phase 2 · recruiting
- NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
- NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
- NCT07126678 — Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma · NA · recruiting
- NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05923502 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 23 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05923502.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing